New eye drug aims to save sight in wet AMD

NCT ID NCT06190093

Completed Disease control Sponsor: Outlook Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. About 400 people with active wet AMD will receive injections of either ONS-5010 or Lucentis into the eye. The main goal is to see if ONS-5010 can prevent vision loss as effectively as Lucentis after 8 weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (also called ONS-5010)
What this could lead to: If successful, this could offer a more affordable treatment option for wet age-related macular degeneration, helping preserve vision.
What could go wrong: This is a Phase 3 trial, so results are not yet confirmed. The drug may not prove as effective as Lucentis, and eye injections carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Clinical Site

Arcadia, California, 91006, United States
Clinical Site

Bakersfield, California, 93309, United States
Clinical Site

Beverly Hills, California, 90210, United States
Clinical Site

Huntington Beach, California, 92647, United States
Clinical Site

Laguna Hills, California, 92653, United States
Clinical Site

Long Beach, California, 90807, United States
Clinical Site

Modesto, California, 95356, United States
Clinical Site

Oakland, California, 94611, United States
Clinical Site

Pasadena, California, 91107, United States
Clinical Site

Poway, California, 92064, United States
Clinical Site

Sacramento, California, 95841, United States
Clinical Site

Colorado Springs, Colorado, 80909, United States
Clinical Site

Lakewood, Colorado, 80228, United States
Clinical Site

Waterford, Connecticut, 06385, United States
Clinical Site

Coral Springs, Florida, 33067, United States
Clinical Site

Fort Lauderdale, Florida, 33308, United States
Clinical Site

Jacksonville, Florida, 32216, United States
Clinical Site

Orlando, Florida, 32806, United States
Clinical Site

Stuart, Florida, 34994, United States
Clinical Site

Oak Forest, Illinois, 60452, United States
Clinical Site

Oak Park, Illinois, 03440, United States
Clinical Site

Carmel, Indiana, 46290, United States
Clinical Site

Lenexa, Kansas, 66215, United States
Clinical Site

Lexington, Kentucky, 40509, United States
Clinical Site

Hagerstown, Maryland, 21740, United States
Clinical Site

Edina, Minnesota, 55435, United States
Clinical Site

Saint Louis Park, Minnesota, 55416, United States
Clinical Site

Jackson, Mississippi, 39202, United States
Clinical Site

Teaneck, New Jersey, 07666, United States
Clinical Site

Albuquerque, New Mexico, 87109, United States
Clinical Site

Liverpool, New York, 13088, United States
Clinical Site

Oceanside, New York, 11572, United States
Clinical Site

Rochester, New York, 14620, United States
Clinical Site

Westbury, New York, 11590, United States
Clinical Site

Asheville, North Carolina, 28803, United States
Clinical Site

Hickory, North Carolina, 28602, United States
Clinical Site

Wake Forest, North Carolina, 27587, United States
Clinical Site

Winston-Salem, North Carolina, 27103, United States
Clinical Site

Edmond, Oklahoma, 73013, United States
Clinical Site

Charleston, South Carolina, 29414, United States
Clinical Site

Florence, South Carolina, 29501, United States
Clinical Site

Ladson, South Carolina, 29456, United States
Clinical Site

West Columbia, South Carolina, 29169, United States
Clinical Site

Rapid City, South Dakota, 57701, United States
Clinical Site

Germantown, Tennessee, 38138, United States
Clinical Site

Abilene, Texas, 79606, United States
Clinical Site

Arlington, Texas, 76012, United States
Clinical Site

Austin, Texas, 78705, United States
Clinical Site

Beaumont, Texas, 77707, United States
Clinical Site

Bellaire, Texas, 77401, United States
Clinical Site

Dallas, Texas, 75231, United States
Clinical Site

Round Rock, Texas, 78681, United States
Clinical Site

San Antonio, Texas, 78240, United States
Clinical Site

San Antonio, Texas, 78251, United States
Clinical Site

The Woodlands, Texas, 77384, United States
Clinical Site

Willow Park, Texas, 79606, United States
Clinical Site

Salt Lake City, Utah, 84107, United States
Clinical Site

Fairfax, Virginia, 22031, United States
Clinical Site

Lynchburg, Virginia, 24502, United States
Clinical Site

Bellevue, Washington, 98004, United States
Clinical Site

Silverdale, Washington, 98383, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.